Imbruvica (ibrutinib)
An approved treatment for Chronic Graft-versus-Host Disease.
The same compound appears under different names depending on the context. Here is how to identify Ibrutinib wherever you encounter it, plus the key facts at a glance.
- Generic name
- Ibrutinib
- Brand name
- Imbruvica
- Development code
- PCI-32765
- Drug class
- BTK inhibitor
- Manufacturer
- Pharmacyclics / AbbVie / Janssen
- How it's taken
- For patients 12 and older, 420 mg by mouth once daily (capsules or tablets).
The first FDA-approved drug specifically for chronic graft-versus-host disease. Ibrutinib blocks both BTK (in B cells) and ITK (in T cells), the two kinases that drive the pathogenic immune attack in cGVHD, while preserving protective immune memory.
Where Ibrutinib fits
Historic first: the first drug ever FDA-approved specifically for chronic GVHD (August 2017). Approved after failure of one or more prior lines, positioning it as a second-line option alongside ruxolitinib. Some centers prefer ibrutinib for patients with prominent GI or skin involvement due to high organ-specific response rates. The preservation of immune memory is an advantage in post-transplant patients at risk for relapse.
How Ibrutinib works
In chronic GVHD, donor B cells produce antibodies against the recipient's tissues while certain donor T cells directly attack organs. Two proteins act as 'on switches' for these immune cells: BTK activates B cells, and ITK activates specific T cell subsets. Ibrutinib permanently blocks both switches by forming an irreversible chemical bond with each protein.
With BTK blocked, B cells cannot produce the tissue-attacking antibodies. With ITK blocked, the pathogenic T cell subsets calm down. Importantly, ibrutinib preserves immune memory cells and a type of T cell (Th1) that helps fight infections, so the patient maintains some ability to defend against infections and monitor for cancer relapse.
In the pivotal study, 67% of patients with steroid-refractory cGVHD responded to ibrutinib, with particularly strong responses in skin and gastrointestinal disease (88-91% response rates in those organs).
Mechanism: Irreversible inhibitor of Bruton tyrosine kinase (BTK) and interleukin-2-inducible T-cell kinase (ITK), blocking B-cell and pathogenic T-cell activation that drives graft-versus-host disease
Side effects and safety
Common side effects include fatigue, diarrhea, bruising, low platelets (thrombocytopenia), mouth sores, muscle spasms, nausea, bleeding, anemia, and pneumonia. More serious effects can include severe infections (pneumonia occurred in 14% of patients) and bleeding events. About 24% of patients discontinued treatment due to side effects, and 26% required dose reductions. The label also warns about serious bleeding, infections, heart rhythm problems, heart failure and sudden death, high blood pressure, low blood counts, second cancers, liver injury, tumor lysis syndrome (a dangerous chemical imbalance when many cells break down at once), and harm to an unborn baby.
This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.
Taking Ibrutinib
For patients 12 and older, 420 mg by mouth once daily (capsules or tablets). Children 1 to under 12 years take 240 mg/m2 once daily (up to 420 mg), and an oral suspension is available. Treatment is continuous until disease progression or unacceptable toxicity. Should avoid grapefruit and strong CYP3A4 inhibitors, which can increase drug levels.
Availability and cost
Only available as the brand-name product.
Help paying for Imbruvica
Pick your insurance to see which help fits. Drugmaker copay cards can't be used with Medicare, Medicaid or TRICARE; charity funds are the usual route there.
- Copay help
Eligible commercially insured patients may pay as little as $0 per prescription with the Copay Card; monthly maximums may apply.
For: private insurance · source - Insurance and case manager help
Nurse Support Line and Insurance Specialists explain benefits, estimate costs and find ways to lower costs for any insurance type, including no insurance.
For: private insurance, Medicare, Medicaid, no insurance · source
Good to know: Copay card excludes Medicare (including Part D and Advantage), Medicaid, TRICARE, DoD and VA. Uninsured patients can call IMBRUVICA By Your Side for help.
- From a charity · TotalAssist (formerly PAN Foundation)Graft-vs-Host Disease (GVHD) fundOpen
Pays for: Out-of-pocket costs for approved medications, up to $9,500 per year. Requires health insurance (any kind).
- From a charity · NMDP (formerly Be The Match / National Marrow Donor Program)NMDP Patient Financial Assistance Grants fundApply directly
Pays for: Out-of-pocket costs before and after blood or marrow transplant, ongoing GVHD treatment costs, clinical-trial travel and financial-crisis grants.
The foundation says: “Status not shown on page”
Clinical trial results
The Phase 1b/2 PCYC-1129 trial enrolled 42 patients with steroid-refractory cGVHD. The overall response rate was 67%. Organ-specific response rates were notably high: 91% in gastrointestinal disease and 88% in skin and mouth involvement. Sustained responses lasting 20 weeks or more occurred in 71% of responders. These results led to the first-ever FDA approval of a drug specifically for cGVHD in August 2017.
Development history
Ibrutinib was developed by Pharmacyclics as a BTK inhibitor for B-cell cancers, gaining its first FDA approval for mantle cell lymphoma in November 2013, followed by CLL in 2014. Preclinical studies at the NIH revealed that both BTK and ITK are essential for cGVHD development in mouse models. This led to clinical testing in cGVHD patients, and FDA approved ibrutinib for cGVHD on August 2, 2017, making it the first drug ever specifically approved for this condition. It is also approved for CLL/SLL and Waldenström macroglobulinemia. Its US indications for mantle cell lymphoma and marginal zone lymphoma were withdrawn in 2023 and no longer appear on the label. In August 2022 the cGVHD indication was extended to children 1 year and older.
Explore Chronic Graft-versus-Host Disease trials
Other Chronic Graft-versus-Host Disease treatments
Common questions about Ibrutinib
▸What is Ibrutinib (Imbruvica)?
The first FDA-approved drug specifically for chronic graft-versus-host disease. Ibrutinib blocks both BTK (in B cells) and ITK (in T cells), the two kinases that drive the pathogenic immune attack in cGVHD, while preserving protective immune memory.
▸How does Ibrutinib work?
In chronic GVHD, donor B cells produce antibodies against the recipient's tissues while certain donor T cells directly attack organs. Two proteins act as 'on switches' for these immune cells: BTK activates B cells, and ITK activates specific T cell subsets. Ibrutinib permanently blocks both switches by forming an irreversible chemical bond with each protein.
With BTK blocked, B cells cannot produce the tissue-attacking antibodies. With ITK blocked, the pathogenic T cell subsets calm down. Importantly, ibrutinib preserves immune memory cells and a type of T cell (Th1) that helps fight infections, so the patient maintains some ability to defend against infections and monitor for cancer relapse.
In the pivotal study, 67% of patients with steroid-refractory cGVHD responded to ibrutinib, with particularly strong responses in skin and gastrointestinal disease (88-91% response rates in those organs).
▸What are the side effects of Ibrutinib?
Common side effects include fatigue, diarrhea, bruising, low platelets (thrombocytopenia), mouth sores, muscle spasms, nausea, bleeding, anemia, and pneumonia. More serious effects can include severe infections (pneumonia occurred in 14% of patients) and bleeding events. About 24% of patients discontinued treatment due to side effects, and 26% required dose reductions. The label also warns about serious bleeding, infections, heart rhythm problems, heart failure and sudden death, high blood pressure, low blood counts, second cancers, liver injury, tumor lysis syndrome (a dangerous chemical imbalance when many cells break down at once), and harm to an unborn baby.
▸How is Ibrutinib taken?
For patients 12 and older, 420 mg by mouth once daily (capsules or tablets). Children 1 to under 12 years take 240 mg/m2 once daily (up to 420 mg), and an oral suspension is available. Treatment is continuous until disease progression or unacceptable toxicity. Should avoid grapefruit and strong CYP3A4 inhibitors, which can increase drug levels.
▸Is Ibrutinib FDA approved?
Yes, Ibrutinib (Imbruvica) is FDA approved (2017) for the treatment of Chronic Graft-versus-Host Disease.
▸Was ibrutinib the first drug approved for chronic GVHD?
Yes. Ibrutinib (Imbruvica) became the first FDA-approved drug specifically for chronic GVHD in August 2017, marking a turning point from corticosteroid-only treatment to targeted therapy.
▸How does ibrutinib work differently from ruxolitinib in GVHD?
Ibrutinib blocks BTK in B cells and ITK in T cells, targeting both arms of the adaptive immune attack. Ruxolitinib blocks JAK1/JAK2, reducing inflammatory cytokine signaling more broadly. Ibrutinib may be preferred for GI and skin-predominant disease.
Sources and references
Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.
- U.S. Food and Drug Administration · August 2, 2017. FDA expands ibrutinib indications to chronic GVHD. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-expands-ibrutinib-indications-chronic-gvhd
- Blood (American Society of Hematology). Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. https://pmc.ncbi.nlm.nih.gov/articles/PMC6033048/
- Pharmacyclics / AbbVie. IMBRUVICA Patient Support. https://www.imbruvica.com/imbruvica-by-your-side